The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis.
Eur J Pharmacol
; 888: 173487, 2020 Dec 05.
Article
in English
| MEDLINE | ID: covidwho-1049775
ABSTRACT
Acute kidney injury (AKI) is an important complication of COVID-19 encompassing a wide range of presentations. SARS-CoV-2 is proposed to cause AKI in the patients through various mechanisms. We are, nevertheless, far from a comprehensive understanding of the underlying pathophysiological mechanisms of the kidney injury in this infection. AKI has been shown to be a marker of disease severity and also a negative prognostic factor for survival. Unfortunately, no effective preventive strategy to decrease the risk of kidney damage in these patients has yet been identified. In this hypothesis, we highlight the potential protective effects of acetazolamide, a carbonic anhydrase inhibitor, in preventing the proximal tubular damage caused by the virus through disrupting the virus-endosome fusion and also interfering with the lysosomal proteases. Our proposed mechanisms could pave the way for further in vitro studies and subsequent clinical trials.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Carbonic Anhydrase Inhibitors
/
Coronavirus Infections
/
Acute Kidney Injury
/
Acetazolamide
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Eur J Pharmacol
Year:
2020
Document Type:
Article
Affiliation country:
J.ejphar.2020.173487
Similar
MEDLINE
...
LILACS
LIS